MAXCYTE, INC. (MXCT): restructuring charge — MaxCyte cuts ~34% of workforce, expects $13.6M annual savings; reiterates 2025 revenue outlook.

MAXCYTE, INC.

Workforce reduction of ~34% globally, including EOR arrangements; expects pre-tax cash charges of $2.9M.
Annualized cost savings estimated at $13.6M, beginning in Q4 2025.
Reiterates 2025 core revenue flat to down ~10% YoY; SPL program revenue ~$5M.
Expects year-end cash, equivalents, and investments to be at least $155M.
Implementation substantially complete by November 2025.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

MAXCYTE, INC. announced a restructuring with charges of approximately $2.9 million affecting global workforce (approximately 34% of the Company’s workforce globally).

Type: restructuring
Charge: approximately $2.9 million
Affected area: global workforce
Headcount: approximately 34% of the Company’s workforce globally

Exact text from the filing

On September 22, 2025, the Board of Directors of MaxCyte, Inc. approved a workforce reduction plan (the “Plan”) as part of the Company’s ongoing efforts to streamline operations, improve its cost structure, and align resources with strategic priorities. The Plan is expected to result in a reduction of approximately 34% of the Company’s workforce globally, which includes both directly employed personnel and individuals engaged through third-party employer-of-record (“EOR”) arrangements. In connection with the implementation of the Plan, the Company currently estimates that it will incur an aggregate of approximately $2.9 million of pre-tax, cash charges.

View on SEC.gov

Browse all restructurings & charges →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-092162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.